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Nucleoside reverse-transcriptase inhibitor (NRTI) therapy for human immunodeficiency virus (HIV) infection has
been associated with mitochondrial DNA (mtDNA) polymerase-g inhibition and subsequent mtDNA depletion.
Effects on mtDNA mutation, although suggested by critical involvement of polymerase-g in DNA-repair reactions,
are unknown. In the present study, we assessed the nature and frequency of mitochondrial genome sequence
differences in peripheral-blood samples taken prior to NRTI therapy and after 6–77 mo of treatment in 16 NRTI-
treated patients. Samples from 10 HIV-infected, treatment-naive control individuals were taken at similar time
intervals. Single-stranded conformation polymorphism (SSCP) and DNA-sequencing analysis techniques were used
to detect mitochondrial genome sequence variants between paired longitudinal samples, and heteroplasmic popu-
lations were quantified after cloning and repeat SSCP/sequencing. Of 16 individuals treated with NRTIs, 5 exhibited
altered SSCP profiles associated with the development of novel heteroplasmic DNA sequence changes, whereas no
SSCP pattern change within these regions was observed in the control individuals. Heteroplasmic sequence changes
were distributed across four regions of the genome: the noncoding region to 12S ribosomal RNA, reduced-nico-
tinamide-adenine-dinucleotide dehydrogenase 1, and cytochrome oxidase subunits I and III. Of the total of 26
patients who were examined in the present study, 4 of 5 patients with detectable mtDNA sequence changes since
commencement of therapy developed evidence of peripheral fat wasting (lipoatrophy) between sample intervals
( ). One patient, without detectable sequence changes on NRTI therapy, also developed lipoatrophy. LevelsPp .031
of mtDNA copies/cell in blood samples were determined by quantitative PCR for 11 of the 16 NRTI-exposed
patients; 7 of these 11 patients showed reduced levels of mtDNA in blood after therapy, including all 3 patients
tested with evidence of mtDNA sequence changes on therapy. These data indicate that NRTI therapy provides
conditions permissive for the development of peripheral-blood mtDNA mutations in vivo.
Introduction
Nucleoside-analogue reverse-transcriptase inhibitors
(NRTIs) were the first agents to be utilized in the clini-
cal treatment of HIV infection and continue to be incor-
porated into contemporary highly active therapy reg-
imens that may combine NRTI drugs with either HIV
protease inhibitors or nonnucleoside reverse-transcrip-
tase inhibitors. Use of these highly effective regimens
has allowed profound suppression of HIV viral replica-
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tion, greatly reducing morbidity and mortality attrib-
utable to HIV-induced immune deficiency (Palella et al.
1998). In this setting, however, a comprehensive under-
standing of the potential that long-term use of antiretrovi-
ral drugs result in adverse effects, including those specifi-
cally associated with NRTI therapy (Kakuda 2000;White
2001), assumes greater importance.
NRTI drugs are nucleoside substrates for the DNA
polymerase activity of HIV reverse transcriptase, act-
ing as DNA chain terminators because of the modifi-
cation of their 3′-hydroxyl group required for nucle-
oside attachment. In addition to the target viral poly-
merase, these compounds also have the capacity to in-
hibit mtDNA polymerase-g, which, unlike nuclearDNA
(nDNA) polymerases, is unable to discriminate effec-
tively in favor of endogenous nucleosides in the pres-
ence of NRTIs (Longley et al. 1998). Polymerase-g is
the sole mtDNA polymerase and is therefore critical
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for synthesis, as well as repair, of the mitochondrial-
encoded genes required for oxidative phosphorylation
and mitochondrial protein synthesis. Hence, mainte-
nance of bioenergetic function in all metabolically ac-
tive cells, including postmitotic cells in which nDNA
synthesis is negligible, requires ongoing uptake and
polymerase-g–dependent utilization of nucleosides by
mitochondria.
The proposal that NRTI-induced polymerase-g inhi-
bition represents a common pathway of tissue-specific
adverse effects of this drug class has been presented by
Lewis and Dalakas (1995). More recently, Brinkman et
al. (1998) have suggested that this process may be rel-
evant to the pathogenesis of a lipodystrophy syndrome
highly prevalent in antiretroviral therapy (ART) recip-
ients. According to this model, cellular—and ultimately
organ—toxicity is proposed to be the consequence of loss
of mitochondrial bioenergetic function, once mtDNA
synthesis has fallen to a level incompatible with cellular
viability. In vitro studies have provided important infor-
mation regarding the possibility that select NRTI drugs
cause DNA polymerase-g inhibition and mtDNA deple-
tion (Martin et al. 1994; Johnson et al. 2001; Birkus et
al. 2002). A consistent ranking has emerged from these
studies, with greatest potency of mtDNA synthesis inhi-
bition attributed to zalcitabine, followed by didanosine,
stavudine, and zidovudine (in that order) and, finally, by
lamivudine, abacavir, and tenofovir (to an equal degree)
(Kakuda 2000).
Research to date has focused primarily on mtDNA
depletion as a product of mitochondrial polymerase-g
inhibition. However, it has also been recognized that
NRTI therapy may also be associated with increased
risk of mtDNA mutation (Lewis et al. 2001), the path-
ogenesis of which is likely to be multifactorial, involv-
ing increased oxidative stress and defective repair.
In the present study, we investigated the impact that
NRTI therapy had on the development of peripheral-
blood mtDNA mutations in 16 HIV-infected individuals,
by comparing the levels of heteroplasmy in samples ob-
tained prior to the commencement of ARTand after 6–77
mo of treatment. A reference group of 10 HIV-infected,
ART-naive individuals was also studied, with paired sam-
ples obtained over a similar time period. SSCP was used
for mutation screening across the entire mitochondrial
genome and paired amplified products exhibiting var-
iations in SSCP profiles were cloned, reamplified, and
rescreened by SSCP. For each of the cloned reamplified
DNA products that demonstrated unique SSCP profiles,
DNA sequencing was undertaken to identify the nature
of the genetic changes.
Patients, Material, and Methods
Patient Characteristics
The study group consisted of 26HIV-infectedpatients,
of whom 16 received NRTI therapy. In the NRTI-treated
group, 14 individuals were participants in clinical trials
and were randomized to receive either stavudine and
lamivudine (7 patients), zidovudine and lamivudine (4
patients), or stavudine and didanosine (3 patients), in
combination with the HIV protease inhibitor indinavir
(OzCombo I ) or the nonnucleoside reverse-[np 11]
transcriptase inhibitor nevirapine (OzCombo II [np
). Additionally, two patients were assessed who, after3]
the introduction of ART, demonstrated clinical features
of lipoatrophy (and are referred to as “symptomatic pa-
tients”), which was accompanied by the development of
symptomatic hyperlactatemia in one patient and by the
rapid enlargement of a subcutaneous hemangioma in the
other patient. Ten HIV-infected ART-naive individuals
were included as control subjects. (For patient demo-
graphics, see table 1.) Informed consent for the use of
human genetic material was obtained from all individ-
uals studied, and the study was approved by the Royal
Perth Hospital ethics committee.
Sample Collection
In individuals participating in clinical trials, paired
DNA samples were obtained from peripheral blood
prior to ART (T1) and after an average of 24 mo on
therapy (T2) (SD 12 mo, range 6–77 mo) (see table
1A). In patient 2, a pretreatment sample was unavail-
able because ART had been commenced interstate, so,
in this case, the T1 sample was obtained after 12 mo
of ART, with a 16-mo interval between the T1 and
T2 samples. In the two symptomatic patients, samples
were obtained prior to the commencement of therapy
and after the development of symptoms (patient 15,
77 mo; patient 16, 47 mo). In the ART-naive patients,
suitable paired blood samples were selected to control
for the effect that HIV had on the levels of mtDNA
mutations. In this group, time between paired samples
averaged 41 mo (SD 23 mo, range 18–92 mo) (see
table 1B).
mtDNA Study
Total genomic DNA was extracted from peripheral-
blood samples obtained at T1 and T2, by conventional
methods. A nested-PCR strategy was adopted, to am-
plify the entire mitochondrial genome. Initial amplifi-
cation of six overlapping regions was achieved by long-
range PCR, using primers designed to exclude known
nuclear-encoded mitochondrial pseudogenes. Details of
primer sequences are available on request. Long-range
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PCR was performed using platinum Pfx DNA polymer-
ase (Life Technologies) under the following amplification
conditions: denaturation cycle at 94C for 2 min; fol-
lowed by 35 cycles of denaturation at 94C for 15 s,
annealing at 58C for 30 s, and extension at 68C at 1
min per kb; and then held at 4C. These products were
used as templates for second-round amplification in a
series of 40 overlapping amplicons of ∼400–800 bp.
Oligonucleotide primers were labeled with fluorescent
HEX or FAM dyes and M-13 sequencing tags, to enable
detection of the PCR products during SSCP and then
during direct sequencing, respectively. The second-round
amplification conditions were as follows: 1 cycle of de-
naturation at 95C for 2 min; followed by 30 cycles of
denaturation at 95C for 20 s, annealing at 60C–65C
for 45 s, and extension at 72C for 90 s; and concluding
with 1 cycle at 4C for 1 min on a CR9600 Thermocycler
(Corbett Research).
SSCP Analysis
Mutational screening was performed by SSCP analysis
on the ABI 310 (Applied Biosystems) under conditions
reported by Witt et al. (2000). In a typical assay, auto-
mated capillary electrophoresis was performed on the de-
natured amplified product (2 ml of PCR product, 10.5 ml
of deionized formamide, 0.5 ml of 0.3-M NaOH, and 0.8
ml of GS 1000 ROX standard) that was injected at 15 kV
for 5 s and was electrophoresed at 13 kV at 30C for 30
min, using a 6% GeneScan polymer and the GeneScan
buffer with EDTA. SSCP analysis within a capillary-gel-
electrophoresis system was performed on the paired T1
and T2 samples, to screen for pattern differences reflect-
ing sequence differences. The relative difference in mo-
bility between the two products was visualized as distinct
patterns in an output graph of the fluorescent intensity
and relative molecular weight. The strand labeled with
the FAM fluorophore consistently demonstrated informa-
tive patterns and was used to characterize the samples.
Differences between interlane electrophoretic mobility of
the DNA were normalized with GS 1000 ROX internal
control within each sample and rarely exceeded 0.5 ap-
parent molecular weight. SSCP patterns that diverged,
between the paired samples, by 11.0 apparent molecular
weight were considered to be different and to probably
reflect sequence changes. Electrophoretic mobility varied
between SSCP runs; hence, matched paired T1 and T2
samples were always included within an SSCP run.
Detection of Sequence Changes
Differences in DNA were identified by comparing the
pattern of elution profiles of the amplified PCR products
of the longitudinal samples. Those exhibiting differences
in SSCP patterns were cloned, reamplified, and rescreened
by SSCP. For the T1 and T2 samples, an example of each
SSCP variant profile identified after cloning was se-
quenced, to determine the nucleotide differences as-
sociated with each of the altered SSCP profiles. For
patient 1, two examples of clones with variant SSCP
profiles were sequenced, and, in both examples, iden-
tical sequences were obtained. Thereafter, only a single
example was sequenced.
pGEM Cloning
Cloning of the PCR product within the pGEM-T Easy
system was performed under conditions recommend-
ed by the manufacturer (Promega). The transformants
were selected, and the purified cloned DNA was used
as a template for reamplification by the appropriate
primers. The amplified cloned products were screened
by SSCP analysis, to identify each DNA population.
Randomly selected clones representative of each SSCP
pattern were sequenced. To confirm that clones with
identical SSCP profiles had identical DNA sequences,
we initially sequenced two examples of clones from a
T1 and T2 sample with identical SSCP patterns. In both
examples, the sequences were identical.
Automated DNA Sequencing
The PCR products were purified using the Bresaspin
PCR purification kit (Bresatec) and were sequenced us-
ing Dye Terminator sequencing chemistry on an ABI 373
DNA Sequencer (Applied Biosystems). Comparison and
analysis were done using the MT Navigator software
(version 1.0; Applied Biosystems).
Quantitative PCR for Measurement of mtDNA
Copies/Cell
mtDNA and nDNA copy numbers were determined
by a quantitative PCR assay using Taqman chemistry
on the ABI 7700 Sequence Detection System platform
(Applied Biosystems). To assess mtDNA content per cell,
we measured the number of copies of a mitochondrial
genome region (the 12S rRNA gene), normalized to a
single-copy region of the nuclear-encoded human growth
hormone (hGH) in independent reactions. Primer and
probe sets used in the assay include the 12S rRNA gene
(forward primer, 5′-TTG GAC GAA CCA GAG TGT
AGC TT; reverse primer, 5′-TTA GCT CAG AGC GGT
CAA GTT AAG; and probe, 6FAM-CAC AAA GCA
CCC AAC TTA CAC TTA GGA GAT TTC A-TAMRA)
and hGH (forward primer, 5′-TAT CCC AAA GGA
CAG AAG TAT TCA TT; reverse primer, 5′-TTG TGT
TTC CCT CCC TGT TGG A; and probe, VIC-5′-ACC
TCC CTC TGT TTC TCA GAG TCT ATT CCG ACA-
TAMRA). Fifty-microliter reactions were performed,
containing 50 ng total DNA; 2.5 mM probe; 15 mM
Table 1
Characteristics of Longitudinal Samples
A. HIV-Infected Patients, before and after Initiation of ART
Patient/Sample ARTa
Time on Therapy
(mo)
mtDNA
Copies/Cellb
Identified mtDNA Region(s)
with Sequence Changes Lipoatrophyc
OzCombo I ( ):np 11
1/T1 Naive 0 289 … No
1/T2 d4T/3TC/IND 49 121 Noncoding to 12S rRNA
(nucleotides 220–1030)
Yes
2/T1 AZT/3TC/IND 12 nd … No
2/T2 AZT/3TC/IND 28 nd Noncoding to 12S rRNA
(nucleotides 220–1030)
No
3/T1 Naive 0 nd … No
3/T2 d4T/3TC/IND 24 nd … Yes
4/T1 Naive 0 106 … No
4/T2 d4T/3TC/IND 25 83 … No
5/T1 Naive 0 102 … No
5/T2 d4T/3TC/IND 23 110 … No
6/T1 Naive 0 nd … No
6/T2 d4T/3TC/IND 18 nd … No
7/T1 Naive 0 176 … No
7/T2 d4T/3TC/IND 18 88 … No
8/T1 Naive 0 75 … No
8/T2 d4T/3TC/IND 6 116 … No
9/T1 Naive 0 46 … No
9/T2 AZT/3TC/IND 26 124 … No
10/T1 Naive 0 93 … No
10/T2 d4T/ddI/IND 40 148 … No
11/T1 Naive 0 119 … No
11/T2 d4T/ddI/IND 17 108 … No
OzCombo II ( ):np 3
12/T1 Naive 0 135 … No
12/T2 d4T/ddI/NVP 8 62 ND1 (nucleotides 3492–3750) Yes
13/T1 Naive 0 79 … No
13/T2 AZT/3TC/NVP 31 nd … No
14/T1 Naive 0 156 … No
14/T2 d4T/3TC/NVP 19 61 … No
15/T1 Naive 0 nd … No
Other ( ):np 2
15/T2 d4T/3TC/IND 77 nd Noncoding (nucleotides 220–627),d
COX I (nucleotides 6841–7276)
Yes
16/T1 Naive 0 172 … No
16/T2 d4T/3TC/IND 47 135 COX III (nucleotides 9111–9635) Yes
B. HIV-Infected, ART-Naive Patients ( )np 10
Patient ARTa
Time between Samples
(mo)
mtDNA
Copies/Cellb
Identified mtDNA Region(s)
with Sequence Changes Lipoatrophyc
17 Naive 33 nd … No
18 Naive 47 nd … No
19 Naive 22 nd … No
20 Naive 34 nd … No
21 Naive 42 nd … No
22 Naive 92 nd … No
23 Naive 73 nd … No
24 Naive 30 nd … No
25 Naive 18 nd … No
26 Naive 25 nd … No
a d4T p stavudine; 3TC p lamivudine; IND p indinavir; AZT p zidovudine; ddI p didanosine; NVP p nevirapine.
b nd p Not determined.
c Diagnosed on the basis of both percentage leg fat and criteria of Mallal et al. (2000).
d Although variant SSCP profiles between the T1 and T2 samples were observed within the noncoding region (nucleotides 220–627), identical
profiles were detected within the overlapping amplicon (extending to nucleotide 1030); hence, the entire region (nucleotides 220–1030) was
not cloned.
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Figure 1 SSCP patterns in NRTI-treated individuals. A, Identical patterns between the pretherapy (T1) and posttherapy (T2) blood
samples. B, Change in SSCP pattern on ART.
forward and reverse primers, respectively; and 2 #
Taqman Universal Master mix (Applied Biosystems).
The amplification conditions were similar for the two
amplicons and included an initial cycle at 50C for 2
min, followed by 1 cycle at 95C for 10 min, and con-
cluding with 45 cycles at 95C for 15 s and 60C for
1 min. The assay exploits Taqman technology, in which
increased accumulation of PCR products is detected
directly by increased fluorescence. The log of the input
DNA is directly proportional to the number of ampli-
fications required to generate a set level of fluorescence.
Plasmid standards of known copy number were used
in the assay, to derive the absolute quantities of mtDNA
in the samples. The number of copies of mtDNA per
cell was determined by normalization of mtDNA con-
tent to nDNA content through use of the following
formula: log10mtDNA/cel l p log1 0mtDNA 
log10nDNA  log100.5. Samples were run in duplicate,
along with replicate controls, and assay performance
was monitored using Shewhart plots, as reported by
Hammond et al. (in press).
Statistical Analysis
Comparisons of mutational change and lipoatrophy
outcome were performed using Fisher’s exact test.
Results
Identification of Variant SSCP Patterns
Different SSCP patterns were observed between the
paired amplicons from five NRTI-treated individuals (ta-
Table 2
Characterization of Heteroplasmic mtDNA Populations—from the Noncoding Region to 12S rRNA
PATIENT/SAMPLE
(NO. OF CLONES
SCREENED)
PATTERN
OF CLONES
(% SIMILAR)a
HETEROPLASMIC NUCLEOTIDE POSITIONS (220–1030)b
263G 275G 302A 309C 382G 398A 410A 431G Cc 466A 513C 522C 523A 524C 587A 601A 614A 624G 633A 697A 710C 740A 744T 756A 815A 825A 869C
1/T1 (27) 1 (78) . . . – . . T . – . . . – – . . . . . . . . . . . . .
2 (11) . . . – . . T . – . . . – – . . . . G . . . . . . . .
3 (11) . . . – . . T . – . . . – – . . . . . . . . . . . . T
1/T2 (30) 1 (37) . . . – . . T . – . . . – – . . . . . . . . . . . . .
2 (33) . . . – . . T . – . . . – – . . . . G . . . . . . . .
4 (10) A . G – . . T . – . . . – – . . . . . . . . . . . . .
5 (7) . . . – . . T . – . – . – – . . . . . G . . . . . .
6 (7) . . . – . G T . – . . . – – . . . . . . T . . . G . .
7 (3) . . . – . . T . – . . . – – . . G . . . . . . . . C .
8 (3) . . . – . . T . – G . . . . . . . . . . . . . . . . .
2/T1 (13) 1 (100) . . . . . . . . – . . . – – . . . . . . . . . . . . .
2/T2 (10) 1 (70) . . . . . . . . – . . . – – . . . . . . . . . . . . .
2 (10) . . . . . . . . – . . . – – . . . . . . . . . G . . .
3 (10) . . . . . . . . C . . . – – . G . . . . T . C . . . .
4 (10) . . . . . . . . – . . . – – . . . . . . . G . . . . .
15/T1 (15) 1 (87) . C . . C . T . – . . . . . . . . A nd nd nd nd nd nd nd nd nd
2 (13) . C . . C . T A – . . . . . G . . A nd nd nd nd nd nd nd nd nd
15/T2 (23) 1 (78) . C . . C . T . – . . . . . . . . A nd nd nd nd nd nd nd nd nd
3 (13) A C . . C . T . – . . . . . . . . A nd nd nd nd nd nd nd nd nd
4 (4) . C . . C . T . – . . . . . . . . T nd nd nd nd nd nd nd nd nd
5 (4) . C . . C . T . – . . – – . . . . A nd nd nd nd nd nd nd nd nd
17/T1 (14) 1 (100) nd nd nd . . . . . – . . . . . . . . . . . . . . . . . .
17/T2 (6) 1 (100) nd nd nd . . . . . – . . . . . . . . . . . . . . . . . .
NOTE.—Nucleotide-sequence variation found in the cloned T1 and T2 samples was identified by examining the cloned insert by amplification, re-SSCP, and sequencing of the clones with unique SSCP patterns.
a SSCP pattern of clones (for details, see the “Results” section); the percentages of clones with similar patterns are given in parentheses.
b Except as otherwise noted, each subheading below gives a heteroplasmic nucleotide position and the corresponding nucleotide in the revised Cambridge reference sequence (GenBank accession number NC_001807). Within the table,
dots (.) indicate identical to the reference sequence, and dashes (–) indicate deletion of a nucleotide; nd p not determined.
c Insertion of nucleotide C between nucleotides 440 and 441 of NC_001807 (GenBank), in patient 2.
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Table 3
Characterization of Heteroplasmic mtDNA Populations—within ND1
PATIENT/SAMPLE
(NO. OF CLONES
SCREENED)
PATTERN
OF CLONES
(% SIMILAR)a
HETEROPLASMIC NUCLEOTIDE POSITIONS (3492–3750)b
3527G 3532G 3539G 3619T 3676A 3684A 3704C 3746G
12/T1 (19) 1 (100) . . . . . . . C
12/T2 (18) 1 (78) . . . . . . . C
2 (6) . . . . . G . C
3 (6) . . . . . . T C
4 (6) . . . C G . . C
5 (6) A C C . . . . C
17/T1 (2) 1 (100) . . . . . . . .
17/T2 (2) 1 (100) . . . . . . . .
NOTE.—Nucleotide-sequence variation found in the cloned T1 and T2 samples was identified by examining the
cloned insert by amplification, re-SSCP, and sequencing of the clones with unique SSCP patterns.
a SSCP pattern of clones (for details, see the “Results” section); the percentages of clones with similar patterns
are given in parentheses.
b Each subheading below gives a heteroplasmic nucleotide position and the corresponding nucleotide in the revised
Cambridge reference sequence (GenBank accession number NC_001807). Within the table, dots (.) indicate identical
to the reference sequence.
ble 1A; e.g., see fig. 1B) in the following four regions:
(1) noncoding to 12S rRNA (nucleotides 220–1030), in
patients 1 and 2, and the noncoding region (nucleotides
220–627), in patient 15; (2) cytochrome oxidase subunit
I (COX I) (nucleotides 6841–7276), in patient 15; (3)
reduced-nicotinamide-adenine-dinucleotide dehydroge-
nase subunit 1 (ND1) (nucleotides 3492–3750), in pa-
tient 12; and (4) ATP6 to cytochrome oxidase subunit
III (COX III) (nucleotides 9111–9635), in patient 16.
mtDNA from paired samples, from most individuals on
NRTI treatment (11/16) and all 10 therapy-naive pa-
tients, exhibited similar SSCP patterns before and after
the interval period (table 1; e.g., see fig. 1A).
Variant profiles were observed in 3 of the 14 subjects
enrolled in trials and in both of the symptomatic patients.
In subjects with evidence of variant profiles, the interval
between samples ranged from 8 mo (patient 12) to 77
mo (patient 15) (table 1A). Patients with variant profiles
from OzCombo I trial (patients 1 and 2) received stavu-
dine/lamivudine for 48 mo and zidovudine/lamivudine
for 16 mo, respectively, and the patient from the Oz-
Combo II trial was treated with stavudine/didanosine
for 8 mo. One symptomatic individual (patient 15) re-
ceived zidovudine/lamivudine/zalcitabine for 3 years,
followed by stavudine/lamivudine (with indinavir) for 2
years (table 1A; previous drug therapy not shown). The
remaining individual with lipodystrophy and hemangio-
ma (patient 16) experienced significant enlargement of the
hemangioma on zidovudine/lamivudine (and indinavir)
therapy, although lipodystrophy had become clinically ap-
parent during previous treatment with stavudine/lamiv-
udine (and lopinavir). Patients were diagnosed with lipo-
atrophy or subcutaneous fat wasting, according to the
criteria of Mallal et al. (2000) (table 1). Of the total of
26 patients who were examined in the present study, 4
of 5 patients with detectable mtDNA sequence changes
during NRTI therapy also developed clinically apparent
evidence of lipoatrophy, whereas lipoatrophy was present
in only 1 of 11 patients without detectable mtDNA se-
quence changes. If we exclude the two nontrial patients
who were included in the study because they became
lipoatrophic on therapy, then the association between
the development of fat wasting and the development of
detectable sequence changes is significant ( ).Pp .031
One patient developed clinically apparent fat wasting
without detectable sequence changes, while treated with
NRTIs.
Analysis of the Cloned PCR Products to Identify
Variant mtDNA Populations
The paired amplified products, across the four
regions from the five patients, that showed initial SSCP
screening differences were cloned, reamplified, and re-
screened by SSCP, to identify the heteroplasmic pop-
ulation. For each of the reamplified cloned products
exhibiting unique SSCP profiles, at least one example
was sequenced, to identify the genetic changes respon-
sible for conferring the unique profile. Details of the
unique SSCP patterns and the number of clones exhib-
iting these patterns with the corresponding mtDNA se-
quence are shown for the four regions, as follows: from
the noncoding region to 12S rRNA (table 2), within
ND1 (table 3), within COX I (table 4), and from ATP6
to COX III (table 5). A substantial increase in the num-
ber of heteroplasmic mtDNA populations was observed
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Table 4
Characterization of Heteroplasmic mtDNA Populations—within COX I
PATIENT/SAMPLE
(NO. OF CLONES
SCREENED)
PATTERN
OF CLONES
(% SIMILAR)a
HETEROPLASMIC NUCLEOTIDE POSITIONS (6841–7276)b
7002A 7029T 7041T 7147A 7154T 7233C 7254A
15/T1 (17) 1 (82) . C . . . . .
2 (18) . C . . . . G
15/T2 (14) 1 (50) . C . . . . .
3 (29) . C C . . . .
4 (14) . C . . C . .
5 (7) G C . G . T .
17/T1 (7) 1 (100) . . . . . . .
17/T2 (3) 1 (100) . . . . . . .
NOTE.—Nucleotide-sequence variation found in the cloned T1 and T2 samples was identified by examining
the cloned insert by amplification, re-SSCP, and sequencing of the clones with unique SSCP patterns.
a SSCP pattern of clones (for details, see the “Results” section); the percentages of clones with similar
patterns are given in parentheses.
b Each subheading below gives a heteroplasmic nucleotide position and the corresponding nucleotide
in the revised Cambridge reference sequence (GenBank accession number NC_001807). Within the table,
dots (.) indicate identical to the reference sequence.
Table 5
Characterization of Heteroplasmic mtDNA Populations—from ATP6 to COX III
PATIENT/SAMPLE
(NO. OF CLONES
SCREENED)
PATTERN
OF CLONES
(% SIMILAR)a
HETEROPLASMIC NUCLEOTIDE POSITIONS (9111–9635)b
9264A 9307T 9378G 9382C 9428C 9438A 9541C 9546A
16/T1 (19) 1 (85) . . A . . . T .
2 (5) . . A T . . T .
3 (5) . . A . . – T .
4 (5) G C A . . . T G
16/T2 (15) 1 (86) . . A . . . T .
2 (7) . . A T . . T .
5 (7) . . A . T . T .
13/T1 (10) 1 (100) . . . . . . . .
13/T2 (6) 1 (100) . . . . . . . .
NOTE.—Nucleotide-sequence variation found in the cloned T1 and T2 samples was identified by examining the
cloned insert by amplification, re-SSCP, and sequencing of the clones with unique SSCP patterns.
a SSCP pattern of clones (for details, see the “Results” section); the percentages of clones with similar patterns
are given in parentheses.
b Each subheading below gives a heteroplasmic nucleotide position and the corresponding nucleotide in the revised
Cambridge reference sequence (GenBank accession number NC_001807). Within the table, dots (.) indicate identical
to the reference sequence, and dashes (–) indicate deletion of a nucleotide.
in T2 samples ( ) compared with T1 samplesnp 27
( ) in the five NRTI-exposed patients in whomnp 11
heteroplasmy was detected ( , log rank).Pp .042
In patient 1, the amplified products from the cloned
pretherapy (T1) blood sample could be assigned to three
SSCP patterns on the basis of the electrophoreticmobility
of the products (tables 2–5). Of the clones, 78% exhibited
a similar profile and were designated as “pattern 1,” and
11% had a similar pattern that was distinct from pattern
1 and were designated as “pattern 2” (fig. 2A); pattern
3 (not shown) was also detected at a frequency of 11%
of the T1-blood-sample clones (table 2).Multiple patterns
were also detected in the T2-sample clones (tables 2–5).
The common SSCP patterns (1 and 2) found in the T1-
blood-sample clones were also common in the T2-sam-
ple clones, at frequencies of 37% and 33%, respectively
(fig. 2A). SSCP pattern 3 was not observed within the
T2 sample despite that 30 clones were analyzed. SSCP
patterns 4, 5, and 6, detected in the posttherapy (T2)
sample, were represented infrequently and were observed
at levels of 10%, 7%, and 7% of clones, respectively (fig.
2B). SSCP patterns 7 and 8 (not shown) were detected at
a frequency of 3% within the T2 DNA sample.
SSCP analyses of clones obtained from the five paired
samples with variant SSCP profiles revealed evidence of
heteroplasmic variants in T1 samples from three patients
(tables 2, 4, and 5). In patients 1, 15, and 16, low-level
heteroplasmic variants that were observed within the T1-
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Figure 2 SSCP patterns in patient 1. A, Identical patterns (1 and 2) in the cloned T1 and T2 samples from patient 1. B, Examples of
unique patterns (4–6), not found in the T1 sample, in the cloned T2 blood sample from patient 1.
sample clones were not detected within the T2 sample.
In some patients (1 and 16), heteroplasmic populations
identified in T1 samples either increased in frequency or
weremaintained at a similar level in the T2-sample clones.
In all cases in which variant SSCP profiles were identified,
however, novel heteroplasmic DNA populations were de-
tected in T2 samples.
SSCP screening was performed on all 10 control
samples, and identical SSCP profiles were obtained in
the T1 and T2 samples. In addition, blood samples
from an HIV-positive ART-naive individual (patient 17),
obtained at T1 and after an interval of 33 mo, were used
as a cloning control sample and were treated similarly.
A single identical SSCP pattern was observed with the
clones obtained from the paired samples, indicating the
absence of detectable mutations associated with the am-
plification or the cloning technique (tables 2–4). Simi-
larly, only one SSCP pattern was detected in the cloned
T1 and T2 samples from NRTI-treated patient 13, in
the region from ATP6 to COX III, providing additional
evidence that the cloning procedure did not introduce
sequence changes (table 5). No evidence of low-level
heteroplasmy was observed in this patient.
Sequence Comparison of the Cloned Products
The mutations conferring the new SSCP patterns were
identified by sequencing the mtDNA insert of one rep-
resentative cloned sample with each unique pattern, and
the sequences were compared with the reference sequence
(GenBank accession number NC_001807). In all cases,
each unique SSCP pattern of the cloned products corre-
lated precisely with a unique sequence genotype (tables
2–5). For example, a sequence comparison of the clones
obtained from the T2 sample from patient 1 indicate that
the clones represented by SSCP patterns 4–8 are unique
and each have at least two mutations when compared to
the sequences obtained from the T1 sample. These mu-
tations are not restricted to the noncoding region and are
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Table 6
Nucleotide Substitutions Observed in the Cloned Samples from the mtDNA Regions (tRNAPhe, 12S rRNA, ND1, COX I, and COX III)
Patient/Sample
Mutation/
Polymorphism Codon Changea Amino Acid Change Synonymous? Locationb Substitutionc
1/T1 A633G NA tRNAPhe Transition
C869T NA 12S rRNA Transition
1/T2 G263A NA
A302G NA
A398G NA
A466G NA
A614G NA
A633G NA tRNAPhe Transition
A697G NA 12S rRNA Transition
C710T NA 12S rRNA Transition
A815G NA 12S rRNA Transition
A825C NA 12S rRNA Transversion
2/T1 …
2/T2 A601G NA tRNAPhe Transition
C710T NA 12S rRNA Transition
A740G NA 12S rRNA Transition
T744C NA 12S rRNA Transition
A756G NA 12S rRNA Transition
15/T1 G431A NA
A587G NA tRNAPhe Transition
15/T2 G263A NA
A624T NA tRNAPhe Transversion
12/T1 …
12/T2 G3527A GCC-ACC A74T No ND1 Transition
G3532C CCG-CCC P75P Yes ND1 Transversion
G3539C GCT-CCT A78P No ND1 Transversion
T3619C TTT-TTC F104F Yes ND1 Transition
A3676G TCA-TCG S123S Yes ND1 Transition
A3684G AAC-AGC N126S No ND1 Transition
C3704T CTG-TTG L133L Yes ND1 Transition
15/T1 A7254G AAC-GAC N451D No COX I Transition
15/T2 A7002G GTA-GTG V366V Yes COX I Transition
T7041C TAT-TAC Y379Y Yes COX I Transversion
A7147G ACT-GCT T415A No COX I Transition
T7154C ATA-ACA M417T No COX I Transversion
C7233T TAC-TAT Y443Y Yes COX I Transversion
16/T1 A9264G ACA-ACG T19T Yes COX III Transition
T9307C TGA-CGA W34R No COX III Transition
C9382T CGC-TGC R58C No COX III Transition
A9546G GGA-GGG G113G Yes COX III Transition
16/T2 C9382T CGC-TGC R58C No COX III Transition
C9428T CCT-CTT P74L No COX III Transition
NOTE.—Randomly selected clones of the paired samples were reamplified and screened by SSCP, to identify each genetic variant. The variants
were sequenced and compared with the reference sequence (GenBank accession number NC_001807). The unique nucleotide substitutions,
along with the predicted amino acid changes, are given.
a NA p not applicable (because the nucleotide substitution occurs in a non–protein-encoding sequence).
b tRNAPhe and 12S rRNA extend from nucleotides 579–649 and 650–1603, respectively.
c Transitions are purine-purine or pyrimidine-pyrimidine substitutions; transversions are purine-pyrimidine or pyrimidine-purine substitutions.
present within the sequence encoding the tRNAPhe, 12S
rRNA, ND1, COX I, and COX III genes (tables 2–5).
Significance of the Nucleotide Substitutions
within the mtDNA
For each of the five patients in whom heteroplasmywas
demonstrated, nucleotide substitutions that were detected
in the coding region within the T1 and T2 samples, com-
pared with the consensus sequence, are described in table
6. Nucleotide substitutions that occurred in all the T1 and
T2 cloned samples—for instance, nucleotide 3746C, in
patient 12 (table 3), and nucleotide 7029C, in patient 15
(table 4)—although different from the consensus se-
quence, were considered to be inherited polymorphisms
and are not included. A number of these substitutions are
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unique and have not been reported before. Many have
occurred at positions that result in a nonsynonymous sub-
stitution in the polypeptide. In the three patients (12, 15,
and 16) in whom the rate of nonsynonymous substitu-
tions could be assessed, there was a trend toward more
nonsynonymous substitutions in the T2 sample ( ),np 7
compared with the T1 sample ( ). The levels of syn-np 3
onymous substitutions in these three patients were similar
in the T2 samples ( ) and T1 samples ( ).np 5 np 4
Measurement of mtDNA Copies/Cell
Levels of mtDNA copies/cell in blood samples were
determined by quantitative PCR for 11 of the 16 patients
who initiated NRTI therapy (table 1A). Of these 11 pa-
tients, 7 showed reduced levels of mtDNA in blood after
initiation of therapy, including all those patients with ev-
idence of mtDNA sequence changes on therapy for whom
mtDNA depletion data was available.
Discussion
The results of this genomewide analysis of peripheral-
blood mtDNA mutations in NRTI-treated individuals
indicate that the use of these drugs provides conditions
permissive for mutagenesis in vivo. The present study
documents the emergence of heteroplasmicmtDNApop-
ulations in peripheral blood, providing evidence that
novel mtDNA sequence variation can arise within in-
dividuals over a relatively brief period. Moreover, these
data suggest that the acquisition of mtDNA mutations
associated with NRTI therapy appears to be a dynamic
process characterized by an increased generation of novel
heteroplasmic populations, without evidence for positive
selection of preexisting non–wild-type sequences.
The mtDNA mutations identified in the present
study were identified by SSCP screening and subse-
quent DNA sequencing, to identify heteroplasmic po-
sitions. Confirmation required the presence of variant
SSCP profiles and DNA sequences in clone popula-
tions. To exclude the possibility that mutations were
generated during the amplification and cloning pro-
cess, we also studied, as a control for cloning exper-
iments, an HIV-positive, treatment-naive individual.
The level of detection for heteroplasmic populations
with SSCP and sequencing techniques was ∼15% in
our laboratory (data not shown), and we acknowl-
edge that the presence of low-level heteroplasmy in
the primary screen and also in other regions of the
mitochondrial genome may have gone undetected. In
this context, it is possible that the heteroplasmic mu-
tant populations that were identified after the intro-
duction of NRTI therapy were present, at a lower
level, in treatment-naive samples. Nevertheless, in the
present study, variant SSCP profiles in paired samples
provided a highly specific screening tool for the iden-
tification of heteroplasmic mtDNA sequence differ-
ences between T1 and T2 samples. This approach
may therefore provide a more broadly applicable ge-
netic screening tool for the investigation of suspected
mitochondrial diseases, utilizing paired samples in
which a high degree of sequence homology is ex-
pected (i.e., within an individual or between matri-
lineally related individuals). Given the high degree of
polymorphic diversity of the mitochondrial genome,
in which coding-region sequence variation is frequent
within and between ethnically distinct haplogroups
(Herrnstadt et al. 2002), pathogenicity of a sequence
variation may be suggested by its development over
time in a symptomatic individual or by its presence
in symptomatic tissues in comparison with unaffected
tissues (Chinnery et al. 1999).
The results of the present study are consistent with a
model in which upregulated cellular oxidative stress, ac-
companied by inhibition of protective DNA-repairmech-
anisms, results in an increased frequency ofmtDNApoint
mutations. Coding and noncoding regions of the genome
were affected, with no evidence for preferential accumu-
lation of mutations either in specific regions or at sites
associated with mitochondrial diseases. Additionally,
NRTI therapy had no consistent effects on heteroplasmic
mtDNA populations present prior to therapy, suggesting
that polymerase-g inhibition does not necessarily provide
an advantage for variant mitochondrial sequences pres-
ent before therapy. It is also notable that, although the
present study was designed to detect sequence variants
in the mitochondrial genome that result from substitu-
tions and small-scale deletions or insertions, the presence
of larger deletions (e.g., the 4,977-bp, “common” dele-
tion) was not assessed. Hence, these data cannot provide
additional insight into possible associations between
NRTI drugs and the development of large-scale deletions.
In this context, it has previously been suggested that trun-
cated mtDNA templates may have a replicative advan-
tage over wild-type sequences and are thus positively se-
lected, in the presence ofNRTI therapy (Wang et al. 1996;
Lewis et al. 2001).
We conclude that NRTI therapy for HIV infection pro-
vides conditions permissive for the development of pe-
ripheral-blood mtDNAmutations in vivo, after 6–77 mo
of drug exposure. The present study has shown that those
NRTI-treated patients who developed sequence changes
within mtDNA also showed decreased levels of mtDNA
in blood on therapy. Further studies will be required in
order to establish and elucidate the bioenergetic and
pathophysiological consequences of these mutations,
which may play a contributory role—alongwithmtDNA
depletion—in the pathogenesis of mitochondrial tox-
icity associated with long-term NRTI therapy.
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